Company Overview - Entera Bio Ltd. is a clinical stage company focused on developing oral peptide and protein replacement therapies in tablet form, addressing significant unmet medical needs [2] - The company utilizes a proprietary technology platform known as N-Tab™ and has a pipeline that includes five differentiated, first-in-class oral peptide programs targeting PTH(1-34), GLP-1, and GLP-2 [2] Product Development - The most advanced product candidate, EB613, is being developed as the first oral osteoanabolic (bone building) once-daily tablet treatment for post-menopausal women with low bone mineral density (BMD) and high-risk osteoporosis [2] - A Phase 2 study of EB613 tablets (n=161) met primary and secondary endpoints related to bone turnover biomarkers and BMD [2] - Entera is preparing to initiate a Phase 3 registrational study for EB613 following FDA's qualification of a quantitative BMD endpoint [2] - The EB612 program is aimed at developing the first oral PTH(1-34) tablet for hypoparathyroidism [2] - The company is also developing the first oral oxyntomodulin for obesity treatment and the first oral GLP-2 peptide tablet for rare malabsorption conditions in collaboration with OPKO Health [2] Upcoming Conferences - Entera Bio will participate in several upcoming conferences, including: - Leerink Partners Global Healthcare Conference on March 12, 2025, in Miami, FL [2] - 2025 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases with an oral presentation on April 11, 2025, and a poster presentation on April 13, 2025, in Rome [2] - 2025 BIO International Convention from June 16-19, 2025, in Boston, MA [2]
Entera Bio to Participate in Upcoming Events